Abstract Background: Visceral leishmaniasis is the most alarming and devastating amongst the various forms of leishmaniases. It is caused by Leishmania donovani, an obligate intracellular parasite of macrophages that survives through immunosuppression. Absence of T regulatory cells provides complete clearance of the parasite. A few immunoprophylactics have been sought to battle instinctive leishmaniasis, with fluctuating achievement. Our previous studies have shown that treatment of L. donovani infected mice with cisplatin along with herbal drugs resulted in decreased parasite load with heightened delayed type hypersensitivity responses (DTH), increased levels of IgG2a, IFN-g, IL-2, CD4þ cells, NK 1.1 cells over that of IgG1, IL-4, 1L-10, CD8þ and CD19 in infected mice. Methods: Along the above lines, the present study further evaluated the percentage of CD4þ CD25þ FoxP3þ T regulatory cells and ultra structural changes in kidney, liver and spleen. Cisplatin (5 mg/kg b.wt. daily for 5 days, i.p.) along with Tinospora cordifolia (100 mg/kg b.wt. daily for 15 days, p.o.) or Withania somnifera (350 mg/kg b.wt. daily for 15 days, p.o.) or Asparagus racemosus (650 mg/kg b.wt. daily for 15 days, p.o.) was administered to L. donovani infected BALB/c and after 30 days post treatment mice were sacrificed. Results: The findings uncover a significant reduction in parasite load coupled with decreased percentage of Treg cells and no pathological changes at ultra structural level. Conclusion: In this manner, results acquired recommend that the decrease in percentage of T reg cells may further help the antileishmanial remedial impact of cisplatin alongside natural medications.
Introduction
Visceral leishmaniasis (VL) is a life threatening systemic disease caused by the parasite L. donovani and is positioned by World Health Organization as the second most paramount disease after malaria. 1 It is a significant reason of morbidity and mortality in East Africa and the Indian subcontinent.
2 90 percent of worldwide VL cases occur in Bangladesh, India (mainly northeastern region) Nepal, Sudan, Ethiopia and Brazil. 3 In Indian subcontinent, the disease has been reported from 109 districts (45 in Bangladesh, 52 in India and 12 in Nepal) with yearly occurrence of 136,500, 270,000 and 12, 600 cases in Bangladesh, India and Nepal respectively. 4 Treatment options for VL are limited. Pentavalent antimonials have viably served as the therapeutic mainstay against leishmaniasis, yet reports of large-scale resistance in India have required assessment of alternative therapeutic modalities. 5 These include amphotericin B together with its liposomal formulation, paromomycin and sitamaquine, however, each have their own limitations of affordability and toxicity and require parenteral administration. Even the orally effective antileishmanial, miltefosine, is associated with gastrointestinal disturbances and teratogenicity. 6 The disease is portrayed by depressed cell-mediated immunity (CMI) and agents which directly stimulate the macrophage to kill intracellular amastigotes 7 through enhanced release of nitric oxide (NO) 8 and/or induce the basic T-helper type 1 (Th1)-cell anti-leishmania immune response would provide a rationale for treatment in visceral infection. 9 Several studies have already been reported emphasizing the benefits of combination of antileishmanial drugs with immunostimulants. 10 Cisplatin is a highly efficient anti-neoplastic drug commonly used as a first-line therapy for treatment of various solid tumors. 11 The anticancer effect of cisplatin is mediated by apoptosis and DNA-crosslinks with subsequent cytotoxic lesions in malignant cells. 12 However, its clinical use is associated with dose and duration-dependent nephrotoxic side effect. 13 Generation of reactive oxygen species (ROS), impaired glutathione metabolism, alterations in the mitochondrial antioxidant enzymes and increase in lipid peroxidation are the most plausible mechanisms of cisplatin induced toxicity.
14 Medicinal plants and natural herbal products have potential antioxidant activity and are therefore often administered along with chemotherapeutic agents to provide better protection against their toxic side effects. 15, 16 Cisplatin has been found to have antileishmanial activity in vitro at a concentration of 0.25e64 mM. 17 It's in vivo antileishmanial activity has also been reported from our laboratory. The treatment of L. donovani infected BALB/c mice with cisplatin resulted in decreased parasite load and it was 81.76% on 21 post treatment day (p.t.d.). However, treatment with cispaltin even at low doses generated nephrotoxicity and hepatotoxicity. 18 Thus, keeping in mind, the immunosuppression caused during visceral leishmaniasis infection and the side effects of the drug cisplatin, we have previously used immunomodulatory and protective herbal drugs T. cordifolia, W. somnifera and A. racemosus along with cisplatin against visceral leishmaniasis. Our results showed decrease in parasite load with enhanced generation of DTH responses, increased levels of Th1 cytokines (IL-2 and IFN-g), IgG2a, CD4þ T cells and NK 1.1 cells. 19,20a,b Evidence from experimental murine models of infection suggests that natural Treg cells promote survival of Leishmania parasites and reactivation of disease. 21 Because immunopathology is thought to play a major role in the pathogenesis of active VL and Treg cells are considered important in the regulatory mechanisms of immunity in VL and there are not any reports regarding the percentage of Treg cells prior and after the treatment, thus we herein, extend our studies to explore the percentages of Treg cells amid infection and after the drug treatment. Additionally, pathological changes have furthermore been observed at the ultra structural level. 
Methods

Animals
Inbred BALB/c mice were purchased from the Institute of Microbial Technology, Chandigarh, India and those at 6e8 week of age were used for the experiment. All mice were maintained at controlled temperature and humidity, with a 12 h light-dark cycle, and sterile food and water ad libitum. Experiments were carried out according to the guidelines of the Committee for the purpose of Control and Supervision of Experiments on Animals (CPCSEA). The ethical clearance for conducting various experiments mentioned in the study on BALB/c mice was taken from Institutional Animal Ethics Committee (IAEC) of the Panjab University, Chandigarh (Approval No. 10/33/CAH). This work was approved by institutional animal ethics Committee.
In vivo infection of mice
The parasites in the logarithmic phase of growth were used for antigen preparation. The culture was pooled and centrifuged for 15 min at 2500 rpm. The supernatant was discarded and the pellet (promastigotes) was washed thrice in PBS. Finally, after last wash, supernatant was discarded and to the remaining pellet, 1 ml of PBS was added. The promastigotes were then counted in the Neubauer's chamber. For this promastigote suspension was diluted in 10% buffered formalin. Promastigotes were then adjusted to a concentration of 10 8 parasites(promastigotes)/ml. Mice were then injected 0.1 ml of this suspension containing 10 7 parasites, intracardially. 
Experimental design
Assessment of infection
Six mice from each group were sacrificed after 30 post infection and post treatment days. Liver parasite burdens were determined from Giemsa-stained multiple impression smears, expressed as Leishman-Donovan Units (LDU) as per the method of Bradley and Kirkley (1977) . Cure can be defined as elimination of parasites to negligible levels.
Flow cytometry
For the immunophenotyping, antibodies viz. CD4 (FITC conjugated), CD25 (APC conjugated) and FOXP3 (PE conjugated), permeabilization buffer and cytofix were purchased from BD Biosciences.
Single cell suspensions from peripheral blood were prepared from all the groups of mice after 30 post infection days (p.i.d.)/post treatment days (p.t.d.) and enriched for lymphocytes using Ficoll-Hypaque density gradient centrifugation. For the determination of percentage of T reg cells, lymphocytes were then stained with antibodies CD4 and CD25 and were kept in dark for 30 min at 4 C. Cells were then washed with wash buffer at 1500 rpm for 5 min. After that supernatant was discarded and to the pellet 60 ml of cytofix was added and it was kept for half hour in dark at 4 C. Fixative was then removed and the pellet was again washed with wash buffer. Supernatant was discarded and to the pellet 400 ml of permeabilization buffer was added and the cells were kept for 10 min. Foxp3 was then added and it was then again kept for half hour in dark at 4 C. As regulatory T cells may express the a-chain of IL-2R, we had used the CD4þ CD25þ T reg cell specific marker Foxp3. The pellet was then again washed in wash buffer and finally resuspended in the same to make final volume of 350e400 ml. Samples were then analyzed on FACSCalibir (B.D) after collecting 10,000 events.
Transmission electron microscopy
Kidney, liver and spleen samples were fixed in 3% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) for 45 min at 26 C, the fixative was discarded and it was replaced with 0.1 M cacodylate buffer and the samples were stored at 4 C until being processed further.
Statistical analysis
All data comparisons were tested for significance by using one-way ANOVA. Results were expressed as mean AE S.D. of one of three independent experiments.
Results
Parasite load
Infected mice upon treatment with cisplatin demonstrated a significant (p < 0.0001) decline in parasite load in terms of LDU as compared with infected control. A percentage reduction of 96.7% was observed. Similarly in the groups of infected mice treated with cisplatin along with T. cordifolia, W. somnifera and A. racemosus, the LDU has been found to be decreased which translated into a parasite removal of 97.1%, 97.2% and 97.2% respectively. Moreover, treatment of infected mice with T. cordifolia, W. somnifera and A. racemosus alone also resulted in decreased parasite load (Fig. 1) . 
Transmission electron microscopy
During observation, kidney micrographs of normal mice showed intact glomerular basal membrane and podocytes in renal corpuscles also appeared intact. However, in cisplatin administered group of infected BALB/c mice there was a prominent mitochondrial degeneration in proximal convoluted tubular cells. These changes were found to be reduced greatly in the groups of infected mice treated with cisplatin along with herbal drugs. In the cisplatin treated infected group of mice paramount cytoplasmic changes appeared in the micrographs of liver, space of Disse was found to be dilated. However, these changes were found to be significantly depressed in the groups of infected mice treated with cisplatin along with herbal drugs. The spleen sections of cisplatin treated infected mice showed heterochromatin condensation in the nucleus of plasma cells. However, after the treatment of infected mice with cisplatin in combination with herbal drugs, normal architecture of spleen was observed (Figs. 5e7).
Discussion
In our previous studies, treatment of L. donovani infected BALB/c mice with cisplatin alone and in combination with Therefore, herein, we now extend the immunomodulatory efficacy of cisplatin alone and in combination with herbal drugs through the evaluation of parasite load along with percentage of Treg cells in experimentally induced visceral leishmaniasis infection in BALB/c mice, thus meriting the use of these drugs against VL infection. For the target parasite (L. donovani), an appropriate laboratory host is very important to carrying on research for the evaluation of antileishmanial action of newer compounds. 21 The BALB/c model fulfills the required eligibility as the chronic infection bears resemblance to human VL. 22 The parasite load was assessed in all the groups of mice on 30 post infection and post treatment days in liver as LDU. 23 The treatment of L. donovani infected BALB/c mice with cisplatin, decreased the parasite load and previous studies have also demonstrated that in vitro antileishmanial activity of cisplatin has also been reported at a concentration of 0.25e0.64 mM.
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A further decrease in parasite load was observed in the infected mice treated with cisplatin in combination with herbal drug T. cordifolia at the dose of 100 mg/kg b.wt. daily for 15 days, orally and the reason that may be responsible for the reduction of parasite burden in infected mice treated with cisplatin in combination with T. cordifolia could be the higher berberine concentration in T. cordifolia. 24 Similarly, significant inhibition in the parasite load was also noticed when cisplatin was administered in combination with W. somnifera in infected mice. The killing of parasites with W. somnifera owes to the presence of withaferin A (steroidal lactone) and withanolide A. 25 The combination of A. racemosus with cisplatin also resulted in comparable clearance of L. donovani parasites from the liver of infected BALB/c mice. This may be due to the involvement of racemoside A, which is an efficacious antileishmanial molecule. This compound showed IC 50 values of 1.31 mg/ml against promastigotes of L. donovani. 26 It can be concluded that maximum parasite clearance was achieved in the groups of mice which included cisplatin in their treatment regime as cisplatin has direct role in killing of parasites and the possible mechanism of parasite killing has been reported to arrest the S and G2 stages of the life cycle of promastigotes and axenic amastigotes. However, complete clearance of the parasites cannot be achieved as elimination of the parasites later depends upon the development and persistence of Th1 responses. 27 Also, apart from the leishmanicidal activities of drugs, Th1 mediated protection plays an important role. 28 Treg cells are the key regulators of immune responses, express CD4, Fox P3 À and CD25 surface markers, and regulate the activation, proliferation, and effector function 29 In experimental models of leishmaniasis, Treg cells seem to play a role in the maintenance of chronic infections, with persistence of pathogens, consequently enabling the disease reactivation. The role of Treg cells in the disease leishmaniasis has been already explored as Foxp3ÀCD4þ cells were found to be the major source of elevated IL-10 mRNA in spleen of VL patient. 30 FoxP3þ T cells are an important source of IL-10 in human VL and that these cells suppress effector T cell activation. 31 Therefore, current study was done to evaluate the increase or decrease in the percentage of Treg cells.
In accordance with the above reports our results also showed that percentage of Treg cells were found to be increased in L. donovani infected BALB/c mice as compared to normal controls.
However, administration of cisplatin to L. donovani infected BALB/c mice decreased the percentage of T reg cells as compared to infected control. Cisplatin is thought to stimulate the immune response by activating macrophages and alternative immune cells. 32 Cisplatin induced macrophage activation leads to the synthesis and release of nitric oxide (critical in parasite killing), TNF-a and IL-1. 33 Authors have also reported the immunomodulatory role of cisplatin pretreatment in a mouse model with colon adenocarcinoma. They observed that pretreatment with cisplatin enhanced the anti-tumor activity of cytokine induced killer (CIK) cells, which share functional properties with both NK cells and T cells 34, 35 by providing CD3þ T lymphocytes into the tumor mass. Moreover, cisplatin also reduced the percentage of intratumoral and splenic Treg cells. 36 The decrease in the percentage of Treg cells in the group of infected mice treated with cisplatin in combination with T. cordifolia, is most probably due to the immunostimulating properties of T. cordifolia. Previous studies have demonstrated that immunity can be enhanced by A. racemosus through T-cells. Steroidal sapogenins and steroidal saponins (shatavaroside A and shatavaroside B) are major secondary metabolites present in A. racemosus that might be attributed to its immunomodulatory effects. 39 In the present study treatment of L. donovani infected BALB/c mice with cisplatin along with A. racemosus reduced the percentage of Treg cells as compared to infected control.
As regards to ultrastructural studies, in cisplatin administered group of infected mice, kidney micrographs showed mitochondrial degeneration in proximal convoluted tubular cells, in the micrographs of liver, space of Disse was found to be dilated and spleen sections showed heterochromatin condensation in the nucleus of plasma cells. However, after the treatment of infected mice with cisplatin in combination with herbal drugs all the above changes have been found to be attenuated. Our results are in accordance with the previous findings where cisplatin administration at the dose of 7.5 mg/kg, i.p. in adult male rats resulted in hemorrhage, glomerular atrophy, inflammatory cell infiltration and tubular necrosis in kidneys. Moreover, at ultrastructural level, the renal corpuscles of cisplatin treated rats showed wide capsular space, fused foot processes, dilated congested capillary loops, irregular capillary basement membrane and mesangial cell hyperplasia with excessive deposited mesangial matrix. Whereas, in the aged garlic extract pre-treated rats, normal podocytes, uniform thickness of the capillary basal lamina and a few dilated congested capillary loops were observed. 40 The protection being provided by the herbal drugs at the ultrastructural level is due the presence of various active constituents in the drugs.
41e43 W. somnifera offers protection due to the presence of active components viz. alkaloids, withanoloids and flavonoids by influencing the levels of lipid peroxidation products, free radical scavenging and antioxidant property. 41 A. racemosus has been found to ameliorate the damage caused to tissue by inhibiting the production and scavenging of free radical through the induction of antioxidant enzymes and improving non-enzymatic thiol antioxidant GSH. 42 The biologically active phytoconstituents of T. cordifolia such as flavonoids and alkaloids may be responsible for its protective activity. 43 Thus, taken, together, these findings suggest that cisplatin in combination with herbal drugs may play a role in attenuating the immunosuppression caused during VL infection by reducing the percentage of Treg cells. Therefore, it is possible to speculate that cisplatin in combination with herbal drug treatment could be used as antileishmanial therapy in future.
